1 / 3

Apaf-1

control. treated. control. treated. E40 - +. E40 - +. E40 40 h. E50 24 h. IP : Apaf-1 WB: AChE. IP: c-IAP-1 WB: AChE. TE671. b -actin. b -actin. IP: c-IAP-2 WB: AChE. IP: Caspase-3 WB: AChE. Sulindac 1 mM, 48 h. E40 24 h. U373MG. b -actin. b -actin.

tala
Download Presentation

Apaf-1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. control treated control treated E40 - + E40 - + E40 40 h E50 24 h IP : Apaf-1 WB: AChE IP: c-IAP-1 WB: AChE TE671 b-actin b-actin IP: c-IAP-2 WB: AChE IP: Caspase-3 WB: AChE Sulindac 1 mM, 48 h E40 24 h U373MG b-actin b-actin IP: Caspase-9 WB: AChE IP: Cyt c WB: AChE HT-29 E10 48 h LY294002 100 M, 24 h SK-MEL5 b-actin b-actin Thapsigargin 2.5 M, 24 h E50 24 h Malme-3M b-actin b-actin SIN-1 1 mM, 24 h SNP 1.5 mM, 24 h RAW 264.7 b-actin b-actin Chondrocyte TRAIL 100 MOI, 72 h IL-3 deprivation BMMC b-actin b-actin HT-29 Chondrocyte RAW 264.7 thapsigargin LY294002 sulindac control control control control control TRAIL control SIN-1 E Apaf-1 Caspase-9 Cyt c IP: AChE Supplementary Fig. S1 A B C

  2. - - + - - + + + E40 si Cyt c Cyt c Hoechst si Cyt c PC 0 8 16 24 48 h IP: Apaf-1 WB: Apaf-1 Apaf-1 HT-29 Thapsigargin 2.5 M 105 IgG IgG 50 IP: Apaf-1 WB: Apaf-1 Apaf-1 Chondrocyte TRAIL 100 MOI 105 IgG IgG 50 IP: AChE si Cyt c 0 8 16 24 48 h PC IP: Apaf-1 WB: Apaf-1 Apaf-1 RAW 264.7 SIN-1 1 mM 105 IgG IgG 50 IP: Apaf-1 WB: Apaf-1 Apaf-1 105 SK-MEL-5 E10 IgG IgG 50 IP: AChE Supplementary Fig. S2 A B

  3. E40 0 8 16 24 48 72 h MbCD E40 - - - + 1/12 + 1 + 2 + 24h + 80 AChE 80 IgG AChE 50 IP : Cav-1 IgG 50 IP: Cav-1 80 AChE E40 0 8 16 24 48 72 h 80 AChE IgG 50 si Cyt c IP: Cyt c IgG 50 IgG IP: Cav-1 50 25 Cyt c IP: Apaf-1 E50 (LNCaP) E10 (PC-3) PC PC 0 24 48 h 0 24 48 h IP: Apaf-1 WB: AChE IP: AChE WB: AChE IP: Apaf-1 WB: AChE IP: AChE WB: AChE IgG IgG IgG IgG IP: Cav-1 WB: AChE IP: AChE WB: AChE IP: Cav-1 WB: AChE IP: AChE WB: AChE IgG IgG IgG IgG IP: Cyt c WB: AChE IP: AChE WB: AChE IP: Cyt c WB: AChE IP: AChE WB: AChE IgG IgG IgG IgG IgG IgG IgG IgG IP: Cyt c WB: Apaf-1 IP: Apaf-1 WB: Apaf-1 IP: Cyt c WB: Apaf-1 IP: Apaf-1 WB: Apaf-1 Supplementary Fig. S3 B A C D E40 0 8 16 24 48 h PC IP: Apaf-1 WB: Apaf-1 Apaf-1 105 IgG IgG 50 IgG IgG 15 IP: Cyt c WB: Cyt c Cyt c 50 IP: Cav-1 E

More Related